NYSE: PFEPfizer Inc Stock
$51.78+1.54 (+3.07%)
Updated Dec 8, 2022
PFE Price
$51.78
Fair Value Price
N/A
Market Cap
$290.66B
52 Week Low
$41.45
52 Week High
$61.71
P/E
9.75x
P/B
3.14x
P/S
2.46x
PEG
N/A
Dividend Yield
3.09%
Revenue
$99.68B
Earnings
$29.77B
Gross Margin
65.6%
Operating Margin
33.31%
Profit Margin
29.9%
Debt to Equity
1.11
Operating Cash Flow
$27B
Beta
0.61
Next Earnings
Feb 6, 2023
Ex-Dividend
N/A
Next Dividend
N/A
PFE Overview
Pfizer Inc. develops and manufactures medicines and vaccines in many therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands, biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands, and sterile injectable and anti-infective medicines and oral COVID-19 treatment under the Sulperazon, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. Pfizer was founded in 1849 and is headquartered in New York, NY.
Zen Score
–
Industry Average (46)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how PFE scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PFE is forecast by analysts to be unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PFE is good value based on its earnings relative to its share price (9.75x), compared to the US market average (21.39x)
P/E vs Market Valuation
PFE is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more PFE due diligence checks available for Premium users.
Be the first to know about important PFE news, forecast changes, insider trades & much more!
PFE News
Valuation
PFE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
9.75x
Industry
32.03x
Market
21.39x
PFE is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
PFE is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
PFE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.14x
Industry
5.63x
PFE is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PFE's financial health
Profit margin
Revenue
$22.6B
Net Income
$8.6B
Profit Margin
38%
PFE's Earnings (EBIT) of $33.20B... subscribe to Premium to read more.
Interest Coverage Financials
PFE's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$195.4B
Liabilities
$102.5B
Debt to equity
1.11
PFE's short-term assets ($70.40B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PFE's short-term assets ($70.40B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PFE's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PFE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$6.0B
Investing
-$627.0M
Financing
-$5.8B
PFE's operating cash flow ($26.60B)... subscribe to Premium to read more.
Debt Coverage Financials
PFE vs General Drug Manufacturer Stocks
Pfizer Stock FAQ
©2022 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.